ABVC BioPharma, Inc. (NASDAQ: ABVC) announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, revealing a substantial 179% increase in total assets to $21.06 million, compared to $7.54 million in 2024. The growth was primarily fueled by strategic acquisitions of land and development-oriented assets in Asia, with net property and equipment rising to $12.84 million from $0.51 million in the prior year. The title transitions to ABVC and its subsidiary are in process.
As of December 31, 2025, the company reported total assets of $21.06 million, property and equipment (net) of $12.84 million, operating lease right-of-use assets of $1.91 million, and long-term investments of $1.88 million. Management believes the 2025 fiscal year represents a structural strengthening of the company’s balance sheet and asset foundation.
ABVC has strategically licensed its core drug programs to subsidiary and related parties: the CNS pipeline to AiBtl BioPharma, oncology programs to OncoX BioPharma, and ophthalmology programs to ForSeeCon Eye Corporation. Under this structure, the subsidiary and related parties handle clinical development, reducing ABVC’s direct clinical cash burn exposure while retaining licensing economics and equity participation. This model separates development risk from long-term value participation.
In parallel with its licensing framework, ABVC is strengthening its long-term infrastructure positioning in Asia through direct and subsidiary strategic land asset acquisitions. In Longtan District, Taoyuan, the company acquired 5,995.41 square meters valued at $4.6 million as of December 31, 2025. The land is held as a strategic reserve asset with flexible future use potential, including healthcare-related applications. In Puli Township, Nantou, ABVC acquired 69,230.90 square meters independently appraised at approximately $8.0 million as of January 30, 2026. The Puli development plan is a staged, long-term initiative focused on establishing a medicinal plant cultivation base, supporting pharmaceutical supply chain localization, and creating an agricultural-biotech integration platform, with projected annual cultivation and processing output value estimated between $60,000 and $360,000.
The potential for a substantial increase in fixed and real assets reflects ABVC’s strategic evolution from a purely IP-driven biotech structure toward a hybrid model combining intellectual property, licensing revenue potential, equity participation in development subsidiaries, and tangible long-term physical assets. As noted in the filing, the company believes this model will continue to benefit it.
ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. The company utilizes in-licensed technology from research institutions including Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the company intends to conduct pivotal clinical trials through global partnerships. More detailed information about the company and risk factors is set forth in its filings with the Securities and Exchange Commission, available at http://www.sec.gov.
